CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Ocoxin-Viusid®dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03717298
NCT03717298Phase 2Completed
CompareCT.gov

Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II

Catalysis SL·interventional·Posted Oct 24, 2018·Updated Mar 28, 2023

In Brief

A Phase 2 clinical trial evaluating Ocoxin-Viusid® for Adenocarcinoma of the Pancreas and 8 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
CountriesCuba
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 24, 2018
Enrollment StartOct 30, 2018
Primary CompletionDec 1, 2022
Study CompletionJan 20, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.7 years ago

Interventions

Ocoxin-Viusid®dietary

An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT. The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment. The treatment will be administered continuously from the inclusion of the patient in the study, up to one year.